In this video, health care analyst David Williamson takes a look back on the week so far for the Food and Drug Administration advisory committee. A trifecta of recommendations for approval greeted investors, although not all thumbs-ups are equal. Watch and find out what this means for investors of the three companies.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.